COMPARISON OF THE PERFORMANCE OF SB2‐INFLIXIMAB WITH ORIGINATOR INFLIXIMAB IN THE MEASUREMENT OF CONCENTRATIONS IN SERUM

Trial Profile

COMPARISON OF THE PERFORMANCE OF SB2‐INFLIXIMAB WITH ORIGINATOR INFLIXIMAB IN THE MEASUREMENT OF CONCENTRATIONS IN SERUM

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 16 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top